We recently published a list of Bitcoin Miners, Quantum Computing Lead Rally: A Look at Wednesday’s Top 10 Gainers.

Needham upgraded its price target for Bitdeer by 57 percent to $22 from $14, while giving it a “buy” rating, indicating an ...

Pharmac has made significant strides in reducing the time required for decision-making processes, particularly for the Named ...

There is an undeniable connection between a strong immune system and nutrition. Learn why what you eat matters and other ways ...

This study identifies key market drivers and trends, aiming to forecast the growth trajectory for each industry in Saudi Arabia over the next few years. The report presents a detailed picture of the ...

On December 20, 2024, the FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

INR:4531. experience the ultimate casino gaming at spreadex "Medical Quick Reading Society" Merck's Erbitux combination therapy ...

The drug has been authorised for use in combination with Erbitux (cetuximab) and mFOLFOX6 (fluorouracil, leucovorin and oxaliplatin) to treat mCRC in patients with a BRAF V600E mutation. Until now, ...

The first arm received encorafenib once orally daily with intravenous cetuximab (Erbitux, Eli Lilly & Co.) every 2 weeks, whereas the second arm received the same as arm 1 in addition to a ...

The FDA granted accelerated approval to the combination of encorafenib (Braftovi), cetuximab (Erbitux), and mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) in metastatic colorectal cancer (mCRC) ...

FDA approved Braftovi, Erbitux, and mFOLFOX6 for BRAF V600E mutation-positive metastatic colorectal cancer. BREAKWATER trial showed a 61% objective response rate for the treatment group versus 40% for ...